Maze Therapeutics (MAZE) Change in Cash (2024 - 2026)

Maze Therapeutics has disclosed Change in Cash across 3 years of filings, most recently posting $9.5 million for Q1 2026.

• Change in Cash for Q1 2026 came in at $9.5 million, down 90.24% year-over-year; the trailing twelve-month figure through Mar 2026 was -$95.6 million (down 136.17% YoY), and the FY2025 annual result was -$7.6 million, down 104.51% from the prior year.
• Change in Cash came in at $9.5 million for Q1 2026 at Maze Therapeutics, up from -$127.5 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $145.0 million in Q2 2024 to a low of -$127.5 million in Q4 2025.
• The 3-year median for Change in Cash is $9.5 million (2026), against an average of $18.8 million.
• Peak annual rise in Change in Cash reached 11178.96% in 2025, while the deepest fall reached 370.16% in 2025.
• Maze Therapeutics' Change in Cash stood at $47.2 million in 2024, then plunged by 370.16% to -$127.5 million in 2025, then surged by 107.46% to $9.5 million in 2026.
• The last three Change in Cash figures came in at $9.5 million (Q1 2026), -$127.5 million (Q4 2025), and $52.2 million (Q3 2025), per Business Quant data.